A randomized phase II study of docetaxel or pemetrexed with or without the continuation of gefitinib after disease progression in elderly patients with non‐small cell lung cancer harboring EGFR mutations (JMTO LC12‐01)

BACKGROUND: Gefitinib (G) is a recommended molecular‐targeted agent for elderly patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC). Docetaxel (Doc) and pemetrexed (Pem) have similar efficacies, and either is often used as the sole agent during treatment....

Descripción completa

Detalles Bibliográficos
Autores principales: Asami, Kazuhiro, Ando, Masahiko, Nishimura, Takashi, Yokoi, Takashi, Tamura, Atsuhisa, Minato, Koichi, Mori, Masahide, Ogushi, Fumitaka, Yamamoto, Akiyoshi, Yoshioka, Hiroshige, Kawahara, Masaaki, Atagi, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200881/
https://www.ncbi.nlm.nih.gov/pubmed/35562327
http://dx.doi.org/10.1111/1759-7714.14465

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200881/
https://www.ncbi.nlm.nih.gov/pubmed/35562327
http://dx.doi.org/10.1111/1759-7714.14465

Ejemplares similares